12:00 AM
 | 
Jun 02, 2008
 |  BioCentury  |  Strategy

A bridge for Sancuso

A bridge for Sancuso

By Aaron Bouchie Senior Writer

JapanBridge Inc. was formed in 2006 with the goal of in-licensing cancer products in late-stage development in the U.S. and Europe, and bringing them to market in Japan. The company recently announced it had taken three big steps toward that goal: in-licensing its first product, assembling a board of advisors with expertise in the Japanese regulatory system, and opening the door to clinical development by incorporating in Japan as JapanBridge K.K.

For its first product deal, JapanBridge chose ProStrakan Group plc's Sancuso granisetron transdermal anti-emetic patch because of the amount of clinical data already available, and the opportunity to capture a portion of the existing market for granisetron in Japan through improved delivery.

JapanBridge also likes the potential for upside in markets outside Japan.

Roche markets oral and injectable versions of Kytril granisetron, a serotonin (5-HT3) receptor antagonist that accounts for 60% of the $300 million Japanese market for 5-HT3 antagonists for chemotherapy-induced nausea and vomiting (CINV).

JapanBridge received exclusive rights to develop and commercialize the patch formulation for CINV in Japan, China and certain countries in Southeast...

Read the full 941 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >